The Scandinavian Simvastatin Survival Study was a study done in 1994 to understand the role of simvastatin in particular and statins in general on the lipid levels in diseased individuals.
In the Scandinavian Simvastatin Survival Study , patients with history of MI (80%) or angina (20%) and raised serum CH level (> 212 mg/dl) were treated with simvastatin or placebo. Simvastatin reduced total CR by 25%, LDL-CR by 35%, raised HDL-CH by 8%. Over a period of 6 years coronary artery disease (CAD) mortality was less by 42%, overall mortality by 30% and cerebrovascular events by 30% in the sirnvastatin group. Similar results as the Scandinavian Simvastatin Survival Study have been obtained with other statins, e.g. the West of Scotland Coronary Prevention Study (WOSCOPS) in men with no history of MI has found pravastatin to lower risk of MI by 31% and all cause mortality by 22%.